NasdaqCM - Nasdaq Real Time Price ? USD Sangamo Therapeutics, Inc. (SGMO) Follow Compare 2.8100 +0.3400 (+13.77%) At close: November 7 at 4:00 PM EST 2.8300 +0.02 (+0.71%) After hours: 7:59 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast RICHMOND, Calif., November 04, 2024--SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 CONFERENCE CALL AND WEBCAST Business Wire ? 3 days ago SGMO +13.77% individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week Key Insights The considerable ownership by individual investors in Sangamo Therapeutics indicates that they... Simply Wall St. ? 6 days ago SGMO +13.77% Merck acquires cancer drug startup; Elevidys ex-US sales rise Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market for its Fabry gene therapy. BioPharma Dive ? 15 days ago ROG.SW CTLT MRK Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 RICHMOND, Calif., October 22, 2024--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 Business Wire ? 16 days ago SGMO +13.77% Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week It is doubtless a positive to see that the Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) share price has gained some 116... Simply Wall St. ? last month SGMO +13.77% Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Just Reported And Analysts Have Been Lifting Their Price Targets The analysts might have been a bit too bullish on Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ), given that the company... Simply Wall St. ? 2 months ago SGMO +13.77% Q2 2024 Sangamo Therapeutics Inc Earnings Call Q2 2024 Sangamo Therapeutics Inc Earnings Call Thomson Reuters StreetEvents ? 2 months ago PFE SGMO +13.77% Genentech and Sangamo to develop neurodegenerative disease therapies Sangamo could receive $1.9bn in development and commercial milestones across multiple products. Pharmaceutical Technology ? 2 months ago SGMO +13.77% Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates Sangamo (SGMO) delivered earnings and revenue surprises of -6.25% and 96.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 3 months ago SGMO +13.77% Sangamo: Q2 Earnings Snapshot RICHMOND, Calif. AP) — Sangamo Therapeutics Inc. SGMO) on Tuesday reported a loss of $36.1 million in its second quarter. Associated Press Finance ? 3 months ago SGMO +13.77% Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results RICHMOND, Calif., August 06, 2024--Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results Business Wire ? 3 months ago SGMO +13.77% Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s. BioPharma Dive ? 3 months ago ROG.SW SGMO +13.77% Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases RICHMOND, Calif., August 06, 2024--Sangamo Announces Epigenetic Regulation and Capsid Delivery Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases Business Wire ? 3 months ago SGMO +13.77% Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast RICHMOND, Calif., July 30, 2024--SANGAMO THERAPEUTICS ANNOUNCES SECOND QUARTER 2024 CONFERENCE CALL AND WEBCAST Business Wire ? 3 months ago SGMO +13.77% Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate RICHMOND, Calif., July 24, 2024--SANGAMO THERAPEUTICS REPORTS ON PFIZER’S ANNOUNCEMENT OF POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF HEMOPHILIA A GENE THERAPY CANDIDATE Business Wire ? 3 months ago SGMO +13.77% Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock? Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. Zacks ? 4 months ago SRPT -5.90% SGMO +13.77% We Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A Microscope Key Insights Sangamo Therapeutics will host its Annual General Meeting on 4th of June Salary of US$716.4k is part of... Simply Wall St. ? 5 months ago SGMO +13.77% US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results The analysts might have been a bit too bullish on Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ), given that the company... Simply Wall St. ? 5 months ago SGMO +13.77% Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript May 9, 2024 Sangamo Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Sangamo Therapeutics First Quarter 2024 Teleconference Call. At this time, all […] Insider Monkey ? 5 months ago SGMO +13.77% Sangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023) Sangamo Therapeutics ( NASDAQ:SGMO ) First Quarter 2024 Results Key Financial Results Revenue: US$481.0k (down 100... Simply Wall St. ? 5 months ago SGMO +13.77% Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return SGMO S&P 500 YTD +420.37% +25.23% 1-Year +538.64% +36.81% 3-Year -74.38% +27.15%
